Scientists distinguished a new class of antibiotics

| By | Antibiotics, Antimicrobial Resistance, R&D

A team of researchers led by Brown University (Providence, USA) infectious disease experts and engineers has identified a new class of antibiotics that could one day help combat the alarming emergence of drug-resistant “superbugs.”

Eleftherios Mylonakis, a professor of infectious diseases at Brown’s Warren Alpert Medical School and chief of infectious diseases at Rhode Island Hospital and the Miriam Hospital, led a multidisciplinary team of researchers searching for drugs to target bacteria that have developed a resistance to conventional antibiotics. Their research led to the identification of two synthetic retinoids, both of which demonstrated the ability to kill MRSA (methicillin-resistant Staphylococcus aureus), a type of staph bacteria that is resistant to several antibiotics. Retinoids, which are chemically related to Vitamin A, are used to treat a variety of health problems, including acne and cancer.

In addition to fellow scientists at Brown, Mylonakis collaborated with researchers from Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Emory University and Northwestern University. The research team developed novel ways to screen a remarkable 82,000 synthetic compounds to identify those that would serve as effective antibiotics but not be toxic to humans. Ultimately, 85 compounds were identified that decreased the ability of MRSA to kill laboratory roundworms. Of those, two, both synthetic retinoids, were selected as the best candidates for further study.

Sophisticated computer modeling and other studies showed that these retinoids impair bacterial membranes. Moreover, these compounds kill so-called MRSA “persister” cells that are drug-resistant dormant cells that are not susceptible to current antibiotic therapies. The ability of the drugs to make bacterial membranes more permeable also appeared to be factor in why they worked well in tandem with an existing antibiotic, gentamicin.

New class of antibiotics has the potential to treat MRSA and other infections that are increasingly resistant to traditional antibiotics.

SOURCE: brown university
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.